Monoamine Neurotransmitter Disorders--clinical Advances and Future Perspectives

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2015 Sep 23

PMID 26392380

Citations 98

Authors

Joanne Ng

Apostolos Papandreou

Simon J Heales

Manju A Kurian

Affiliations

Soon will be listed here.

Abstract

The monoamine neurotransmitter disorders are important genetic syndromes that cause disturbances in catecholamine (dopamine, noradrenaline and adrenaline) and serotonin homeostasis. These disorders result in aberrant monoamine synthesis, metabolism and transport. The clinical phenotypes are predominantly neurological, and symptoms resemble other childhood neurological disorders, such as dystonic or dyskinetic cerebral palsy, hypoxic ischaemic encephalopathy and movement disorders. As a consequence, monoamine neurotransmitter disorders are under-recognized and often misdiagnosed. The diagnosis of monoamine neurotransmitter disorders requires detailed clinical assessment, cerebrospinal fluid neurotransmitter analysis and further supportive diagnostic investigations. Prompt and accurate diagnosis of neurotransmitter disorders is paramount, as many are responsive to treatment. The treatment is usually mechanism-based, with the aim to reverse disturbances of monoamine synthesis and/or metabolism. Therapeutic intervention can lead to complete resolution of motor symptoms in some conditions, and considerably improve quality of life in others. In this Review, we discuss the clinical features, diagnosis and management of monoamine neurotransmitter disorders, and consider novel concepts, the latest advances in research and future prospects for therapy.

Citing Articles

Serotonin signaling to regulate energy metabolism: a gut microbiota perspective.

Li G, Dong S, Liu C, Yang J, Rensen P, Wang Y Life Metab. 2025; 4(2):loae039.

PMID: 39926388 PMC: 11803461. DOI: 10.1093/lifemeta/loae039.

The Neurometabolic Function of the Dopamine-Aminotransferase System.

Apryatin S Metabolites. 2025; 15(1).

PMID: 39852364 PMC: 11767981. DOI: 10.3390/metabo15010021.

Monoamine transporter ubiquitination and inward-open conformation synergistically maximize transporter endocytosis.

Sorkina T, Bagalkot T, Cheng M, Guthrie D, Newman A, Watkins S Sci Adv. 2024; 10(47):eadq9793.

PMID: 39576869 PMC: 11584022. DOI: 10.1126/sciadv.adq9793.

Parkinson Disease -Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation.

Liu Z, Xiang S, Chen B, Li J, Zhu D, Xu H Adv Sci (Weinh). 2024; 11(46):e2404717.

PMID: 39431293 PMC: 11633476. DOI: 10.1002/advs.202404717.

L-Dopa Might Be Insufficient to Suppress Development of Prolactinomas in Dihydropteridine Reductase-Deficiency Patients.

Diaz-Moreno U, Gan C, Pujari D, Gan H, Batzios S JCEM Case Rep. 2024; 2(10):luae172.

PMID: 39346013 PMC: 11427838. DOI: 10.1210/jcemcr/luae172.

References

Giovanniello T, Leuzzi V, Carducci C, Di Sabato M, Artiola C, Santagata S . Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. Neuropediatrics. 2007; 38(4):213-5. DOI: 10.1055/s-2007-991151. View

Crabtree M, Tatham A, Al-Wakeel Y, Warrick N, Hale A, Cai S . Quantitative regulation of intracellular endothelial nitric-oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem. 2008; 284(2):1136-44. DOI: 10.1074/jbc.M805403200. View

Lenders J, Eisenhofer G, Abeling N, Berger W, Murphy D, Konings C . Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest. 1996; 97(4):1010-9. PMC: 507147. DOI: 10.1172/JCI118492. View

Stamelou M, Mencacci N, Cordivari C, Batla A, Wood N, Houlden H . Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology. 2012; 79(5):435-41. PMC: 3405253. DOI: 10.1212/WNL.0b013e318261714a. View

Dill P, Wagner M, Somerville A, Thony B, Blau N, Weber P . Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. Neurology. 2012; 78(5):e29-32. DOI: 10.1212/WNL.0b013e3182452849. View

Yildiz O, Smith J, Purdy R . Serotonin and vasoconstrictor synergism. Life Sci. 1998; 62(19):1723-32. DOI: 10.1016/s0024-3205(97)01166-1. View

Hwang D, Ardayfio P, Kang U, Semina E, Kim K . Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res. 2003; 114(2):123-31. DOI: 10.1016/s0169-328x(03)00162-1. View

Leuzzi V, Carducci C, Tolve M, Giannini M, Angeloni A, Carducci C . Very early pattern of movement disorders in sepiapterin reductase deficiency. Neurology. 2013; 81(24):2141-2. DOI: 10.1212/01.wnl.0000437299.51312.5f. View

Palfi S, Gurruchaga J, Ralph G, Lepetit H, Lavisse S, Buttery P . Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet. 2014; 383(9923):1138-46. DOI: 10.1016/S0140-6736(13)61939-X. View

10.

Reinhardt P, Schmid B, Burbulla L, Schondorf D, Wagner L, Glatza M . Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013; 12(3):354-67. DOI: 10.1016/j.stem.2013.01.008. View

11.

Pons R, Syrengelas D, Youroukos S, Orfanou I, Dinopoulos A, Cormand B . Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord. 2013; 28(8):1058-63. DOI: 10.1002/mds.25382. View

12.

Millner M, Franthal W, Thalhammer G, Berghold A, Aigner R, Fuger G . Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children. Clin Chem. 1998; 44(1):161-7. View

13.

Willemsen M, Verbeek M, Kamsteeg E, de Rijk-van Andel J, Aeby A, Blau N . Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain. 2010; 133(Pt 6):1810-22. DOI: 10.1093/brain/awq087. View

14.

Assmann B, Surtees R, Hoffmann G . Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann Neurol. 2003; 54 Suppl 6:S18-24. DOI: 10.1002/ana.10628. View

15.

Timmers H, Deinum J, Wevers R, Lenders J . Congenital dopamine-beta-hydroxylase deficiency in humans. Ann N Y Acad Sci. 2004; 1018:520-3. DOI: 10.1196/annals.1296.064. View

16.

Arnoux J, Damaj L, Napuri S, Serre V, Hubert L, Cadoudal M . Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia. J Clin Endocrinol Metab. 2013; 98(11):4279-84. DOI: 10.1210/jc.2013-2740. View

17.

Graziano C, Wischmeijer A, Pippucci T, Fusco C, Diquigiovanni C, Noukas M . Syndromic intellectual disability: a new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant. Gene. 2015; 559(2):144-8. DOI: 10.1016/j.gene.2015.01.026. View

18.

Horvath G, Stockler-Ipsiroglu S, Salvarinova-Zivkovic R, Lillquist Y, Connolly M, Hyland K . Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol Genet Metab. 2008; 94(1):127-31. DOI: 10.1016/j.ymgme.2008.01.003. View

19.

Chen P, Lee N, Chien Y, Wu J, Wang P, Hwu W . Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clin Chim Acta. 2014; 431:19-22. DOI: 10.1016/j.cca.2014.01.034. View

20.

Montioli R, Dindo M, Giorgetti A, Piccoli S, Cellini B, Borri Voltattorni C . A comprehensive picture of the mutations associated with aromatic amino acid decarboxylase deficiency: from molecular mechanisms to therapy implications. Hum Mol Genet. 2014; 23(20):5429-40. DOI: 10.1093/hmg/ddu266. View